Pharmaceutical Contract Manufacturers: Unleashing the future of contract manufacturing
Roots Analysis
Market research & consulting services in the pharma / biopharma, medical devices & contract manufacturing domains
The manufacturing of novel small molecule drug candidates requires specialized facilities, advanced equipment and operational expertise. As a result, the pharmaceutical companies might encounter difficulties in conducting development and manufacturing operations independently. Additionally, time and cost-intensive nature of setting up or acquiring manufacturing capabilities has prompted both small and big pharmaceutical companies to increasingly outsource their manufacturing operations to contract manufacturing organizations (CMOs) and contract development and manufacturing organizations (CDMOs). In addition, the imperative need for safer and more effective drugs has further increased the demand for contract manufacturing services.
Driven by the need for enhanced efficiency, traceability and cost-effectiveness, pharmaceutical contract manufacturing is undergoing technological advancements. Outsourcing manufacturing operations to CMOs and CDMOs entails the implementation of specialized solutions to optimize production workflows, ensure regulatory compliance, and maintain product quality standards. Furthermore, there is a growing emphasis on personalized medicinal products, necessitating flexible manufacturing capabilities to meet diverse patient needs. As pharmaceutical companies navigate these evolving dynamics, the demand for advanced solutions tailored to the unique requirements of contract manufacturing services is expected to rise over the forecast period.
For detailed information:
Email: sales@rootsanalysis.com
Current Market Landscape: Pharmaceutical Contract Manufacturers
The current landscape features the presence of close to 425 CMOs offering contract manufacturing services for small molecules. It is worth mentioning that there has been a steady rise in the number of small molecules manufacturing companies over the past decade, indicating a growing demand for capacities manufacturing both novel and conventional drugs. Further, a significant proportion of the companies (57%) offer services for both API manufacturing and FDF manufacturing to small molecules developers; notable examples include Acino, Glatt, Chemigran, AllChem Laboratories, Fujimoto Chemicals, Isochem, API Pharmatech, Afton Scientific and Nectar Lifesciences.
Key Trends in the Pharmaceutical Contract Manufacturing Market
Stakeholders in the pharmaceutical contract manufacturing industry have forged several deals in order to acquire various manufacturing companies or production facilities. It is worth highlighting that more than 90% of deals were inked for acquiring manufacturing facilities. CDMOs acquire facilities to expand their geographical presence. In one such instance a German CDMO, Adragos Pharma, acquired a manufacturing facility for oral solids from Sanofi. This deal took place in October 2022 for Kawagoe, Japan facility.
Recommended by LinkedIn
Additionally, this segment of the global contract manufacturing market has seen rapid growth after the COVID-19 pandemic. Notably, the majority of these deals are focused on acquisition of companies, followed by facility acquisition. This can be attributed to the incessant efforts of small molecules CMO to further advance the development of their product offerings, across different phases.
Leading Pharmaceutical Contract Manufacturing Organizations
Examples of key players offering contract manufacturing services for small molecules (which have also been profiled in this market report) include (in alphabetical order) AMRI Global, Altasciences, Cambrex, Catalent, DPT Laboratories, Aenova, Almac, Corden Pharma, Fresenius Kabi, Glatt, Hovione, Recipharm, Siegfried, CMIC Group, Nectar Lifesciences, Syngene and WuXi AppTec. This market report includes an easily searchable excel database of all the pharmaceutical CMO and details on their manufacturing facilities worldwide.
All your Questions Related to Pharmaceutical Contract Manufacturing Market Answered in this Report
The Pharmaceutical Contract Manufacturing Market: Industry Trends and Global Forecasts, till 2035 report features an extensive study of the current market landscape, market size and future opportunities associated with the pharmaceutical contract manufacturing market, during the given forecast period. Further, the market report highlights the efforts of several stakeholders engaged in this rapidly emerging segment of the meat industry. The report answers many key questions related to this market. Click on the below link to know more about this emerging area of research.
About Roots Analysis
Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights.